Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

February 18, 2022

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 34 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Catherine, serving as the conference operator for today. At this point, I'd like to welcome all of you to the 2021 third quarter earnings conference call for Cronos Group. This call is being recorded as of now. Right now, I'll hand things over to Shayne Laidlaw from Investor Relations. Go ahead, please.

Shayne Laidlaw

executive
#2

Thank you, Catherine, and thanks to everyone for being with us today as we go over Cronos Group's financial and business performance for the third quarter of 2021. With me on the call are our president and CEO, Kurt Schmidt, our CFO, Bob Madore, and our executive chairman, Mike Gorenstein. This morning Cronos Group put out a news release announcing these financial results, and it has been filed on our EDGAR and SEDAR profile. That information, along with the prepared remarks, will be posted on our website under investor relations as well. Before handing the call over to Kurt, I'd like to remind you that during this conference call our discussion will include forward-looking statements. Those statements rest on assumptions that carry risks and uncertainties, and actual results could differ materially from what the forward-looking statements project, including because of the factors set out in the cautionary statements and risk factors contained in the company's earnings release and regulatory filings, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and any forward-looking statements made during this call are qualified in their entirety by those documents. I want to stress that this call will be limited to third quarter of 2021 earnings and the restatement of our second quarter financial statements, and we will not be addressing or taking questions on full year 2021 results.

Shayne Laidlaw

executive
#3

Results for the full year 2021 are going to be talked through once our annual report on Form 10-K has been filed with the SEC. Also, on this call, some financial measures could come up that aren't recognized under U.S. generally accepted accounting principles, which the Securities and Exchange Commission calls non-GAAP measures. In our view, these non-GAAP measures help management with planning, forecasting, and evaluating business and financial performance, including how resources get allocated. Reconciliations of these non-GAAP measures to the most comparable reported GAAP measures appear in our earnings press release furnished to the SEC, and you can find it in the press room section of our website, thecronosgroup.com. These non-GAAP measures might not be comparable to measures other issuers use. I'd also like to point out that we are holding today's call from our respective remote locations. Because of that, brief delays, crosstalk, or minor technical issues may occur during this call. We thank you in advance for your patience and understanding. We'll now give prepared remarks, and after that we will move into a question-and-answer session. With that, I'll hand things over to Cronos Group's President and CEO, Kurt Schmidt.

Kurt Schmidt

executive
#4

Thank you, Shayne, and good morning to all of you. I'd like to express appreciation to our employees, our Board of Directors, and our shareholders for standing by us and being patient while we finish the Q2 restatement and complete our Q3 filings. Extra-special thanks go out to the finance and legal teams for going above and beyond during the last few months. Situations like this are never simple, yet learning from them and growing is vital. Continuous improvement is something we're dedicated to, and we have indeed learned and evolved as a result of this situation. At this point I'd like to go over recent developments concerning our financial reporting and internal controls, along with the remediation steps we're taking, and Bob will walk you through further specifics on those items in just a moment. As we mentioned in November 2021, the audit committee of the company's Board of Directors collaborated with our independent financial auditors on a review to assess the goodwill and the indefinite-lived intangible assets in the U.S. reporting unit for impairment. From that review, we recorded impairment charges on the U.S. reporting unit totaling $236.1 million with respect to goodwill and indefinite-lived intangible assets, as well as on long-lived assets, in the three months ended June 30th, 2021. As a result, the company has restated that period's financial statements to reflect this new information.

Kurt Schmidt

executive
#5

The restatement doesn’t affect cash and cash equivalents or revenues at all. These matters are important to us, and as part of the restatement, we began changing our internal control policies and procedures so that internal controls over financial reporting are further strengthened. In addition, we’re carrying out a realignment of the business that we believe will put Cronos in the best position to generate profitable, sustainable growth over time. I see the realignment as having three distinct pillars. First, we have realigned the organization so that our go-forward strategy is better supported. That involves centralizing functions under common leadership, which lets us allocate resources more efficiently, improve strategic alignment, and remove duplicative roles and costs. Second, we will cut complexity, which will lead to lower fixed expenses. We are evaluating our global supply chain so that it becomes leaner and so that we can adapt more quickly to the changing landscape. We are conducting product reviews, optimizing pricing, and pursuing distribution across North America that matches our go-forward strategy. We remain steadfastly focused on aligning department priorities and team structure in support of these initiatives. Finally, we will put an operating expense target in place to help us optimize how we deploy cash. With more states legalizing cannabis in the U.S., we are eager to build on our investment in PharmaCann to bring adult-use THC products and brands to the U.S.

Kurt Schmidt

executive
#6

Once it's federally legal, consumers will be there. Through our strategic investment in PharmaCann, we've laid the groundwork to enter that market, and our current operations in Canada and other international markets are giving us valuable experience. Thanks to our new organizational structure, we'll be in an ideal position to enter and deliver. The overall strategic realignment initiative is projected to generate $20 million-$25 million in initially identified savings across operating expense categories in 2022, mainly from savings in sales and marketing, general administrative, and research and development. Under the first pillar of our realignment, which centralizes decision-making under common leadership, Cronos appointed Jeff Jacobson as Senior Vice President, Head of Growth. Mr. Jacobson previously was the company's General Manager of Canada and Europe. He has been with Cronos Group since December 2016 and, before that, was a Co-Founder of Peace Naturals. His expertise and experience in licensing and compliance, new business development, project management, and resource management will help Cronos Group lead in domestic and international markets. The company also named John Griese as Senior Vice President, Head of Operations. Mr. Griese came to Cronos Group in August 2021 as the Vice President of Operations.

Kurt Schmidt

executive
#7

Mr. Griese has collaborated with a number of cannabis companies, and most recently he served as Chief Operating Officer at the Supreme Cannabis Company. Before joining Supreme, Mr. Griese gained cannabis expertise while California was implementing its adult-use market, serving as COO at Creso Pharma Ltd., a global cannabis company. Before that, the bulk of his career was spent in supply chain and operations roles at PepsiCo, Nestlé, and Sofina Foods. His know-how in constructing supply chains across the globe is going to help the company succeed in the markets where we operate today, while remaining nimble enough to move quickly and pivot as the industry shifts over time. I have confidence that these realignment efforts will put Cronos in a better position to keep assembling a portfolio of best-in-class brands and intellectual property, while preserving the financial flexibility needed to make further strategic investments in our R&D pipeline and brands as we keep innovating and evolving alongside what our consumers want and need. Our structure going forward will be a brand-centered organization, with teams focused on accelerating growth on the core, margin and creative innovation, winning in rare cannabinoids, entering the U.S. adult use market, and streamlining the organization so it makes better decisions while boosting alignment and agility. There is plenty to look forward to as this process unfolds, and updates will be provided in the quarters ahead.

Kurt Schmidt

executive
#8

Meanwhile, we're staying focused on moving these initiatives ahead, pushing our core business priorities forward, and getting ready to enter the U.S. While we're confident that our realignment strategy will make a difference in certain parts of the business, I think Cronos is in a great spot within the global cannabis landscape, and that's a credit to Mike Gorenstein's prudent leadership during the early days of legalization in Canada and the shifting landscape around the world. From day one, Cronos has taken a different path. Rather than aiming for a multiple of unfunded capacity, we stayed relatively lean and concentrated on R&D while building cultivation partnerships with large-scale agricultural specialists. Rather than controlling positions in countries outside the U.S., Canada, and Israel, we opted for low capital-intensive partnerships that create exposure while limiting risk. Rather than wanting to be first to market, we concentrated on differentiation and on delivering products that consumers didn't know were possible. While this approach wasn't the most popular and calls for patience from our shareholders, partners, and employees, we're starting to see it pay off. The success we're seeing shows up in point-of-sale data. Our SOURZ by Spinach edibles reached double-digit market share in the gummies category in Canada within six months of launching, and our breeding and genetics program has produced some of the best-selling high-THC flower SKUs on the market in Canada.

Kurt Schmidt

executive
#9

We didn’t get to those rankings first, but after we moved ahead with those product launches, we demonstrated the capability throughout our company and the determination to succeed. The Canadian adult-use market has been and remains something we view as a test-and-learn market. Everyone understands the reasons it is not the simplest market in which to operate, yet our focus is on making it work for us. That involves concentrating on reducing losses while keeping profitability in mind, and above all, creating products through extensive R&D that produce turnkey solutions for every market where we operate. Cronos does face difficulties and has made missteps. We recognize that, and through this strategic realignment we are working to address them. At the same time, we feel considerable confidence because we hold one of the industry’s strongest balance sheets and have strength throughout our organization, which I believe positions Cronos to lead in any market where we operate. Now I’ll turn to updates on some of the items that are working today. In October 2021, we introduced Canada’s first cannabis edible containing cultured CBG, SPINACH FEELZ Chill Bliss 2:1 THC/CBG gummy. After that successful launch, in January 2022 we launched a 1 g THC vape pen containing cultured CBG, further extending our leadership position and bringing high-quality, rare cultured cannabinoids to the market.

Kurt Schmidt

executive
#10

After the third quarter ended, we reached the equity milestone for cultured CBGVA, and that represents an essential step toward creating cultured THCV. We take real pride in what we're achieving alongside Ginkgo and in how we're setting the company up to succeed with rare cannabinoids. A new platform from the Spinach brand, Spinach FEELZ, is going to offer a range of cannabis products, and those will feature rare cannabinoids made through our proprietary processes, which are designed to deliver a unique and enhanced experience. Just as a reminder, Cronos holds the view that the surest path to lasting success in cannabis is competing through differentiated products rather than simply battling on price. We believe we've executed that strategy very well with Spinach, our flagship adult-use brand, by giving consumers better products and delivering strong overall value, and we're only at the beginning. Under the second pillar of our strategic alignment, we're carrying out product and brand reviews throughout our portfolio, and we've made the decision to discontinue sales of the COVE brand in Canada. During the past year, we've sharpened our focus on expanding Spinach across categories. We think we have something extraordinary with the Spinach brand. It will carry over to other markets when the timing is right. Down the road, there could be chances for other brands to join the adult-use cannabis market in Canada at varying price tiers.

Kurt Schmidt

executive
#11

At the moment, our top priority is Spinach, which is our highest ROI brand. We'd also like to share an update on Cronos GrowCo. In Q3 2021, we began buying biomass that GrowCo produced for our Canadian operations. Cronos has consistently held the view that partnering with large-scale agriculture specialists is a strategic approach to constructing an efficient supply chain. Early wins from GrowCo have shown that our instincts were right, and it's gratifying to watch our vision for this partnership become reality. Our medical business in Israel keeps delivering exceptionally strong results, recording yet another quarter of robust top line growth. We take pride in what we've achieved in that market and in building relationships with patients and distributing to almost every pharmacy that stocks medical cannabis. A recent survey released by Cannabis Magazine found that our Peace Naturals brand ranked as the most recognized brand within Israel's medical cannabis market — a genuine testament to the team's work in Israel. As of December 2021, roughly 109,000 cannabis patients are registered in Israel, a figure that's 40% higher than the same period a year earlier. We think this market remains in the early stages of growth, which presents Cronos with a strong opportunity to keep expanding our Peace Naturals brand among medical consumers in Israel.

Kurt Schmidt

executive
#12

Now on the U.S. side, Jeff Jacobson has stepped into his new position as Head of Growth, and he's working closely with his team to get deep into that business — every one of those people played an essential part in what we achieved in Canada. Jeff is spearheading a review of the entire portfolio, which will in all likelihood involve optimizing pricing, rationalizing SKUs, and going after distribution channels that fit the strategy we're moving forward with. In our U.S. CBD portfolio, Jeff and his team have had plenty of strong products at their disposal. Going forward, our efforts will center on steering future innovation toward items that line up better with our ambition of being an adult-use cannabis company, with a sharp emphasis on doing fewer things better and a firm requirement around return on investment. A straight-line recovery isn't what we anticipate, though we're eager to walk you through how this evolves as time goes on. While we restructure the organization so that it fits the strategy we're pursuing, the bulk of our energy will go toward lifting our brands through the use of rare cannabinoids and a focus on adult-use products. There's substantial work in front of us, yet I have confidence in what we're doing to demonstrate the strength of our business.

Kurt Schmidt

executive
#13

Having said that, I'd like to extend a welcome to Bob Madore on his debut earnings call since becoming Cronos Group's new CFO. Bob, the floor is yours.

Bob Madore

executive
#14

Thanks, Kurt, and good morning, everyone. As Shayne said in his opening remarks, my discussion is confined to the results for the third quarter of 2021 and the restatement of our second quarter financial statements. I won't be addressing or taking questions about our full year results for 2021. Before I get into the financial results for the third quarter of 2021, let me talk about the impairment charges and the restatement of the second quarter of 2021 that we announced today. The company has restated its second quarter of 2021 financial statements to reflect a total of $236.1 million impairment charge with respect to goodwill and indefinite-lived intangible assets and long-lived assets in the U.S. reporting unit. This restatement is non-cash in nature, so therefore it does not impact cash equivalents, or revenues. We are taking action to improve internal policies and procedures and strengthen internal controls. These efforts include bolstering the talent across our finance organization to help implement stronger internal controls. Kurt and I are leading the reinforcement of company policies and procedures, making enhancements to our sub-certification process and clawback policy to drive additional accountability, and expanding training programs for our finance personnel. We take these matters very seriously as Kurt and I walk you through, and we're committed to taking action.

Bob Madore

executive
#15

Moving on to how we performed in Q3 2021. Consolidated net revenue came in at $20.4 million for that quarter, which was up 80% compared with the same period a year earlier. The year-over-year top-line gain came mainly from ongoing expansion of the Canadian adult-use cannabis market, higher sales in Israel's medical market, and stronger sales in the U.S. segment. Consolidated gross profit for Q3 2021 stood at -$0.7 million, which was a $0.8 million improvement over the third quarter of 2020. That gain against the prior year was driven chiefly by more sales of cannabis extracts in Canada, a category that delivers a higher gross profit than other product types. I'll go deeper into this line item shortly, segment by segment, since each business is being shaped by different dynamics. Adjusted EBITDA for the third quarter of 2021 was -$46.8 million, a decline of $16.7 million versus the third quarter of 2020. That year-over-year drop stemmed mainly from higher general administrative expenses, which were driven by a $13.2 million increase in the allowance for expected credit losses, along with greater sales and marketing spend, largely tied to brand development in the U.S.

Bob Madore

executive
#16

That segment, plus higher R&D from spending on product development and on building cannabinoid intellectual property. Now to our reporting segments. For the rest of the world segment, net revenue in the third quarter of 2021 came in at $18.3 million, which is an 88% increase from the prior year period. The year-over-year revenue growth was mainly driven by growth in the adult-use flower and extract categories in Canada, along with sales in the Israeli medical cannabis market. Gross profit for the Rest of the World segment in the third quarter of 2021 was $0.6 million, which represents a $2.8 million increase from the third quarter of 2020. The increase versus prior year was primarily driven by an increase in sales of cannabis extracts in the Canadian market, which carries a higher gross profit than other product categories. We've experienced some price compression in certain categories, such as vape, where differentiation is a bit harder to achieve. While we were more insulated from those dynamics in certain flower SKUs and edibles given our superior product quality and differentiation. We are happy with our progress on gross profit and believe the realignment that Kurt spoke to will further enable Cronos Group to improve the trajectory of this line item across our businesses and regions over time.

Bob Madore

executive
#17

For the Rest of the World segment, third-quarter 2021 adjusted EBITDA came in at negative $29.8 million, which is a $15.4 million drop compared with the third quarter of 2020. That year-over-year decrease was mainly caused by higher G&A expenses — largely from a $13.2 million rise in the allowance for expected credit losses, which we discussed earlier — along with growth in headcount, more spending on R&D, and higher sales and marketing costs. Now moving to the U.S. segment: net income for the third quarter of 2021 was $2.1 million, up 28% versus the prior-year period. The year-over-year revenue growth was driven mostly by launching new CBD products. As Kurt mentioned, the U.S. CBD business isn't performing the way we'd like. Jeff Jacobson and his team are still in the early phase of realigning that business strategy. Gross profit for the U.S. segment in the third quarter of 2021 was negative $1.3 million, a $2 million decrease from the third quarter of 2020. That year-over-year decline stemmed primarily from larger inventory valuation adjustments and higher production costs. Adjusted EBITDA for the U.S. segment in the third quarter of 2021 was negative $12.2 million, a $6.5 million decrease from the third quarter of 2020.

Bob Madore

executive
#18

The year-over-year drop came mainly from higher sales and marketing costs tied to brand development, plus an increase in general and administrative expenses. Now let's look at our cost savings initiatives. As Kurt mentioned, we've started a strategic realignment that we expect to deliver $20 million-$25 million in initially identified savings across operating expense categories in 2022, driven primarily by savings in sales and marketing, general and administrative, and research and development costs. This realignment centers on right-sizing the cost structure so it better aligns with our go-forward plans. We're concentrating on the highest ROI opportunities, further embedding the mentality of doing fewer things better. During our internal analysis, we took special care to make sure cost reductions wouldn't inhibit growth. You'll see continued investment in revenue-generating activities. And going forward, operating expenses will aim to be more directly tied to a percentage of revenue. Turning to the balance sheet. The company finished the quarter with approximately $1 billion in cash and short-term investments, which is down approximately $60 million from the second quarter of 2021. Capital expenditures for the quarter were $2.5 million, with the spending focused across our global strategic priorities. Capital expenditures are down approximately 70% year-over-year, driven by reduced spending on enterprise resource planning implementation and capital improvements across our facilities.

Bob Madore

executive
#19

Our approach to putting capital to work stays disciplined, and we'll only do so in ways that match up with what we've set as strategic priorities. With that said, I'll hand things back over to Kurt.

Kurt Schmidt

executive
#20

Thank you, Bob. The strategic realignment we've started putting into place is an initiative that spans the whole company. In each function, we're looking for ways to cut duplication and bring capability into a centralized structure, which makes us more efficient and cost-effective as an organization. A focused return to doing fewer things better is what these changes are built around. We stay committed to launching best-in-class adult use cannabis products on the market, with rare cannabinoids serving as a core differentiator. As we work through the realignment, our focus is on not losing sight of what is working today — continuing to elevate the Spinach brand and grow its leading market position in Canada, and bringing high-quality medical cannabis to Israeli medical patients under the Peace Naturals brand. Those remain our top priorities. I'm looking forward to all the new things we have planned from a brand and product perspective across our global portfolio in 2022 and beyond. With that, I'll open it up for questions.

Operator

operator
#21

Thanks. If you’d like to ask something, press star one on your phone. If you want to take your question back, hit the pound key. Also, please keep it to 1 question plus 1 follow-up. Our first question is from John Zamparo at CIBC. Your line is open.

John Zamparo

analyst
#22

Thank you, and good morning. I'd like to begin with the strategic realignments, and specifically you brought up a cut in R&D expenses. I'm curious how you're thinking about that, since R&D appears quite central to the strategy — both in biosynthesis and more broadly in creating differentiated products. Do you feel that a lot of your R&D work is already complete, or is there another factor at play here? I'd just like to get a clearer picture of that portion of the strategic update, please.

Kurt Schmidt

executive
#23

This is Kurt. What it comes down to is concentrating our R&D on the categories and business segments that truly move performance. I named two of those areas earlier. The first is innovation that adds to margin, with a real emphasis on adult use cannabis products that we think can deliver that. SOURZ stands out as a strong example on the edible side. The second area is succeeding with rare cannabinoids. We stay highly focused, and much of our work centers on bringing these sorts of differentiators to market. Every function, R&D included, always has efficiencies available. As we move further into the adult use segment, we believe we'll be fully equipped to drive the innovation we have planned for the coming few years.

John Zamparo

analyst
#24

Thanks. My next question concerns how margins are structured. What I want to get at is what you're aiming for, since you've doubled sales in rest of world while also seeing a bit of margin expansion. That figure remains negative, yet my thinking is that sustaining sales growth at roughly that rate would deliver fairly strong leverage on that line. Does the strategic review include a push to make the cost base more variable? To me, Cronos has never looked like a business that has to be a manufacturer. Is your aim to shift the cost structure toward more variable costs and outsource a greater share of production, especially in Canada?

Bob Madore

executive
#25

Absolutely, John — Bob here. Appreciate the question. Yeah. Clearly, growing sales is a major priority for us, but one thing that's less a change and more of a deeper emphasis is going after innovation opportunities, along with product categories and products that can genuinely deliver profitable sales growth. Another point — and this is a big part of the strategic realignment Kurt devoted considerable time to discussing — is truly assessing our supply chain and making us not only more agile but also more cost competitive. There are quite a few items we're evaluating and examining on that front. Rest of the World, I'd say, is one illustration this quarter: posting a positive gross margin stands as evidence of our attention there and of some early wins in that area, along with certain revenue mix shifts that produce better gross margin. The realignment's other dimension is essentially reviewing our cost structure, right-sizing it to match where the business actually stands today and where our growth plans point, and simply being more strategic about where we put our dollars — whether that's R&D, as Kurt more or less addressed in response to your question, or sales and marketing and, you know, G&A.

Bob Madore

executive
#26

This is a multipronged effort — a strategic alignment plan, you know — and it's sharply aimed at driving real impact throughout the whole P&L.

John Zamparo

analyst
#27

Okay, got it. Thanks so much.

Operator

operator
#28

Thanks. We’ll take the next question from Rahul Sarugaser at Raymond James. Your line is open.

Rahul Sarugaser

analyst
#29

Morning, Kurt and Bob. We really appreciate you both making time for our questions.

Kurt Schmidt

executive
#30

Morning, everyone.

Rahul Sarugaser

analyst
#31

Let me start by concentrating briefly on the revenue line this morning. You said the U.S. has been somewhat underwhelming. The American market, as we've observed, has taken longer to develop than a lot of folks expected. Turning to Canada, we have witnessed fairly solid improvements in share of the edibles segment, mainly because of your distinctive offerings. Yet, given that flower still accounts for the bulk of that market, how ought we to view Cronos's share gains from here — both regarding its organic expansion, thanks to those differentiated fermentation-derived products, and also when it comes to more conventional flower-based items?

Kurt Schmidt

executive
#32

So first, I want to say that flower remains a major piece of the business's overall scope, and in Canada it continues to perform extremely well for us. It reached above 90% during the quarter, and that result is really powered and guided by our focus on THC strains and distinctive genetics, areas where we've achieved a great deal of success.

Rahul Sarugaser

analyst
#33

All right, thanks a lot. I’ll keep this brief with one follow-up, this time about the fermentation-derived products. Again, we’ve witnessed fast share gains in Canada in that area. How ought we to view the worldwide rollout of those rare cannabinoid fermentation-derived products?

Kurt Schmidt

executive
#34

I mean, that's still in front of us. I mean, out of the eight molecules we intend to pursue, only two have been reached so far. We still want to build it. Keep in mind that Canada serves as a test market. We are growing this brand in Canada. Once the portfolio is rounded out — and early results on our first edible are fantastic, as I mentioned in the script — then everything lies ahead of us, right? We are still in the early stages of developing it. Certainly that, as we said regarding Canada, it is a test market. It establishes the platform for our brand to move forward in other markets.

Rahul Sarugaser

analyst
#35

Thanks a lot. Appreciate you answering our question. We’ll rejoin the queue.

Operator

operator
#36

Our following question is from Andrew Carter at Stifel. Your line is open.

Andrew Carter

analyst
#37

Hey, thanks, and good morning. My first question concerns the delayed 10-Q filing—I’d assume the 10-K is still on track for March. What I’m asking about all of that is whether any kind of regulatory restrictions come out of this. Will you still be able to issue equity for acquisitions, or are you in the penalty box? Just help us out on that first.

Bob Madore

executive
#38

Right. Apart from the management cease trade order tied to our late filings — which, as of today, we've caught up on — there aren't any regulatory restrictions. As for getting our 10-K filed on schedule, we don't expect any delays to our ability to do that.

Andrew Carter

analyst
#39

Thanks. For my second question — I get the Cronos story, and I understand that Canada serves as a test market for future opportunities, especially in the U.S. So I suppose, given the cost savings, the expense target, and now this kind of realignment, is it possible to be profitable, or at least close to break-even cash flow, with the market opportunities you currently have in hand — Canada adult use and medical, Israeli medical, and also some of the opportunistic global medical markets? Thanks.

Bob Madore

executive
#40

Sure, I'll handle that one — and Kurt, feel free to jump in with some color at the end of my answer. Look, we're extremely focused, and a major piece of the strategic realignment is really about continuing to push the Rest of the World segment toward profitability, right? This quarter's results and what we've been seeing so far have us quite encouraged. That's a massive priority within it. As Kurt mentioned, Canada is more of a test-and-learn market. Given current market dynamics, turning a profit there is tough. At minimum, we're very encouraged by the progress so far and by what we expect in the very near future — we definitely have the ability to be more profitable than we are today. The other great thing, you know, is that with our innovative pipeline, we not only lead in flower — and we've got three of the top 10 strains out there at the end of the day — but we're very, very excited about the growth and market share gains we've seen in other categories, like vapes, like edibles. We've shown we can grow categories beyond just flower, and we're going to keep building on that.

Bob Madore

executive
#41

You know, the extracts side of the business also carries a better gross margin, and that is only going to help Canada's profitability profile even more. That is squarely in the sights of our realignment strategy, which Kurt sort of walked through.

Andrew Carter

analyst
#42

Thank you. Over to you.

Kurt Schmidt

executive
#43

Yes. Yeah, our brands are excellent, and we’re proving we can propel them forward—that gives me a lot of optimism regarding Canada.

Andrew Carter

analyst
#44

Alright.

Operator

operator
#45

Thanks. That's all the time we have for questions. This concludes today's conference call and thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.